Pharmanovia A/S: Financial statements 2015
CVR: 32287824
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
Pharmanovia A/S (CVR 32287824) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 1,474,795 and a net result of DKK -2,189,034 compared with DKK -3,404,393 the year before. Equity in the 2015 report amounted to DKK -12,347,072. The company had 4 employees in the financial year.
- Gross Profit
- DKK 1,474,795
- Profit/Loss
- DKK -2,189,034
- Equity
- DKK -12,347,072
- Total Assets
- DKK 18,656,169
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 1.5 mio. | -2.2 mio. | -12.3 mio. | 4 |
| 2014 | - | -609 t. | -3.4 mio. | -10.2 mio. | 4 |
| 2013 | - | -1.2 mio. | -6.7 mio. | -6.8 mio. | - |
| 2012 | - | -157 t. | -586 t. | -60 t. | - |
Official annual report
How creditworthy is Pharmanovia A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of December 31, 2015, Svend Aage Johansen has left the board of directors of Pharmanovia A/S.
As of December 31, 2015, Bent Benny Andersen has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2014. Gross profit came to DKK -608,728, and the net result was DKK -3,404,393.
About Pharmanovia A/S
Pharmanovia A/S is a Danish company of the type Aktieselskab based in København S, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Atnahs Pharma Nordics A/S and PHARMANOVIA A/S. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. The company has 3 employees (2026). In 2026, the company reported a gross profit of EUR 11,734,813 and a net result of EUR 7,730,657 compared with DKK 3,839,334 the year before. Equity in the 2026 report amounted to EUR 15,820,601.